Back to results
US 8,278,335 B2Granted
Inhibitors of Janus kinases
AssigneeMerck Sharp & Dohme Corp.
InventorsMichelle R. Machacek, Andrew Haidle, Anna A. Zabierek, Kaleen M. Konrad, Michael D. Altman
Life of this patent
Estimating the term…
Abstract
The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.
Claims9
A compound of the formula
- wherein W is N or CR3;
- R1 is substituted aryl or substituted heteroaryl, wherein said aryl and heteroaryl groups are independently substituted with one to three substituents selected from the group consisting of halo, hydroxyl, C1-6 alkyl, C1-6 haloalkyl, (C1-6 alkyl)OH, (C1-6 alkyl)CN and heterocyclyl;
- R2 is hydrogen, C1-6 alkyl, (C1-6 alkyl)OH or SOm(C1-6 alkyl);
- R3 is hydrogen, C1-6 alkyl or (C1-3 alkyl)O(C1-6 alkyl);
- wherein said alkyl groups are optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl, cyano, C1-6 alkyl, C1-6 haloalkyl, (C1-6 alkyl)OH, heteroaryl (which is optionally substituted with C(O)NR4R5) and heterocyclyl;
- or R2 and R3 can be taken together with the carbon atoms to which they are attached to form a five or six membered heterocyclic ring, which is optionally substituted with one to two substituents independently selected from the group consisting of C1-3 alkyl or oxo;
- R4 is hydrogen or C1-3 alkyl,
- R5 is hydrogen or C1-3 alkyl,
- m is an integer from zero to two;
- or a pharmaceutically acceptable salt or stereoisomer thereof.
7 more elements
Dependencies are inferred from the claim text.